EUCTR2005-001628-35-CZ进行中（未招募）不适用
A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation - MMVAR
The European group for Blood and Marrow Transplantation (EBMT)0 个研究点目标入组 452 人开始时间: 2006年8月21日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 452
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- •Male or female and at least 18 years-of-age
- •Histologically confirmed diagnosis of multiple myeloma with evaluable disease parameters (see attachment, Criteria for the diagnosis of myeloma)
- •Relapsing or having a progressive disease at least one year after an autologous transplantation as defined by Bladé et al criteria (section 8.2) :
- •Relapse as defined by one of the following:
- •1. Reappearance of serum or urinary paraprotein in immunofixation or routine electrophoresis, confirmed by at least one further investigation and excluding oligoclonal immune reconstitution.
- •2. >5% plasma cells in a bone marrow aspirate or on trephine bone biopsy
- •3. Development of new lytic bone lesions or soft tissue plasmacytomas or definite increase in the size of residual bone lesions. Development of a compression fracture does not exclude response.
- •4. Development of hypercalcemia, corrected serum calcium >11.5mg/dL or 2.8 mmol/L, that is not attributable to any other cause
- •Progressive disease as defined by one of the following:
- •- 1/ > 25% increase in the level of the serum monoclonal paraprotein (5 g/l increase minimum and at least two investigations)
- •- 2/ > 25% increase in the 24 h urinary light chain excretion (200 mg/d increase minimum and at least two investigations)
- •- 3/ > 25% increase in plasma cells in a bone marrow aspirate (absolute increase of at least 10%)
- •- 4/ increase in the size of existing bone lesions or soft tissue plasmacytomas
- •- 5/ new bone lesions or soft tissue plasmacytomas
- •- 6/ onset of hypercalcemia not attributable to any other cause
- •Measurable disease defined as: quantifiable serum monoclonal antibody defined as a serum monoclonal protein >1g/dL for IgG, or >0.5g/dL for IgA
- •Karnofsky performance status > 50 %
- •Life expectancy of at least 3 months
- •Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.. Male subject agrees to use an acceptable method for contraception for the duration of the study.
- •Negative serum or urine ß-HCG pregnancy test at screening for subjects of child-bearing potential
- •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients meeting any of the following exclusion criteria are not to be enrolled in the study.
- •Patients with non-secretory MM
- •Karnofsky performance status < or equal to 50%
- •Patient has a platelet count < 40,000 ? 109/L within 14 days before enrollment.
- •Patient has an absolute neutrophil count <1.0 ? 109/L within 14 days before enrollment.
- •Patient has a calculated or measured creatinine clearance <30 mL/minute within 14 days before enrollment.
- •Patient has ?Grade 2 peripheral neuropathy within 14 days before enrollment.
- •Seropositive for HIV, or active hepatitis A, B or C infection
- •Patient has hypersensitivity to bortezomib, boron or mannitol.
- •Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum ?-human chorionic gonadotropin (?-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
- •Patient has received other investigational drugs with 14 days before enrollment
- •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- •Previous or concurrent malignancies at other sites, with the exception of appropriately treated localized epithelial skin or cervical cancer. Patients with remote histories (>5 years) of other cured tumors may be entered
- •Poorly controlled hypertension or diabetes mellitus or other serious medical or psychiatric conditions that could interfere with adherence to or completion of this study
- •Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis.
研究者
相似试验
进行中（未招募）
不适用
A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation (MMVAR). - MMVAR - originally also known as Velcade IISEUCTR2005-001628-35-ATEuropean Group for Blood and Marrow Transplantation (EBMT)452
进行中（未招募）
不适用
A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation (MMVAR). - MMVAREUCTR2005-001628-35-HUEuropean Group for Blood and Marrow Transplantation (EBMT)452
进行中（未招募）
1 期
A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation (MMVAR). - MMVARMale or female subjects, 18 years-of-age or older, with multiple myeloma who received at least one autologous transplantation and who have responded and later progressed or relapsed at least one year after transplantationEUCTR2005-001628-35-GBEuropean Group for Blood and Marrow Transplantation (EBMT)452
进行中（未招募）
1 期
A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation (MMVAR). - MMVAREUCTR2005-001628-35-DEEBMT Clinical Trial Office452
进行中（未招募）
1 期
A randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation - MMVARmultiple myeloma patients in progression or relapse after autologous transplantationEUCTR2005-001628-35-BEEBMT - CLWP452